SSShivali Singla

Shivali Singla

*This is an algorithmically generated author record based on publicly available information.

Shivali Singla has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Matteuccia struthiopteris (L.) Todaro (fiddlehead fern): an updated review

    by Shivali Singla, Rupali Rana, Surendar Kumar, Reena Thakur, Sachin Goyal

    Background: Matteuccia struthiopteris(L.) Todaro is a popular edible wild fern found in the subtropical Himalayas. It is widely used in folk medicine to treat several ailments and known for its antioxidant, anti-inflammatory, antibacterial, antiviral and antidiabetic activities. Due to its multidimensional nutritional, pharmacological and therapeutic effects, it is well recognized in the Ayurvedic Pharmacopoeia.Main body of The present review aims to provide updated information onMatteuccia struthiopterisbotany, phytochemistry, pharmacological effects and toxicity methods, in addition to highlight potential for future exploration. Particular emphasis is also given to its antioxidant potential in health promotion. In-depth literature was probed by examining numerous sources via online databases (research and reviews), texts, Web sites and thesis. Plant biotechnology approaches such as tissue culture and micropropagation are also discussed.Short conclusion: Matteuccia struthiopterisis found useful in the treatment of different diseases such as microbial infection, viral infection and diabetes and in weight reduction and also effective as antioxidant and free radical scavenger. Nevertheless, advance studies are required to offer the mechanistic role of crude extracts and its bio-actives and even to discover the structure–function relationship of active principles.


  • Open Access

    Green synthesis of silver nanoparticles using Oxalis griffithii extract and assessing their antimicrobial activity

    by Shivali Singla, Abhishek Jana, Reena Thakur, Chinu Kumari, Sachin Goyal, Joohee Pradhan


  • Open Access

    Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences

    by Shivali Singla, Sachin Goyal

    Background: The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and safety of molnupiravir in clinical trials.Main body: Information on publications was explored on several databases, gray literature was reviewed, and the outcomes were discussed narratively. Molnupiravir's antiviral efficacy and associated mechanism of action have been verified in vitro against both non-COVID and multiple coronaviruses. Molnupiravir has been tried in preclinical investigations in numerous animal models against non-coronaviruses. Clinical studies in several countries are now being conducted to evaluate its antiviral efficacy in persons infected with COVID-19. The medication displays antiviral effect via generation of copying mistakes during viral RNA replication.Conclusions: Molnupiravir is the first oral antiviral medicine to show considerable and convincing antiviral activity in vitro and in animal models. Molnupiravir stops the spread of SARS-CoV-2 in animals that have been infected and in cells grown in a lab. In a clinical research, early molnupiravir treatment reduced hospitalization and death risk in unvaccinated individuals with COVID-19. In the battle against SARS-CoV-2, it could be a potent weapon. However, its role in COVID-19 in moderate to severe cases is still up in the air, and more research is needed.


  • Open Access

    Different Therapeutic Aspects of Peroxisomes Proliferator-Activated Receptors

    by Shivali Singla, Chetna Jhagta, Sachin Goyal, Abhishek Kumar

    Peroxisome proliferator-activated receptors (PPARs) were discovered in 1990 and belong to the steroid hormone receptors superfamily. Three PPAR subtypes have been discovered so far: PPARα, PPARβ/δ, and PPARγ. Human peroxisome proliferator-activated receptors (hPPARs) were initially identified as therapeutic targets for production of drugs to treat metabolic disorders, such as diabetes and dyslipidemia but now they are used in energy burning, dyslipidemia, diabetes, inflamm

  • Open Access

    Evidence of carrier mediated transport of ascorbic acid through mammalian cornea

    by Shivali Singla, D.K. Majumdar, Sachin Goyal, Gurudas Khilnani

    The purpose of the present study was to evaluate the transport of ascorbic acid, a water soluble molecule, through a predominantly lipophilic cornea. Thus in-vitro permeation of ascorbic acid from aqueous drops through freshly excised mammalian cornea was studied. Aqueous isotonic ophthalmic solutions of ascorbic acid of different concentrations (0.125% w/v to 2% w/v) (pH 5.4) were made. Further 1.0% w/v or 0.5% w/v ascorbic acid solution containing NaCl or dextrose as tonicity modifiers or Na(+)K(+)-ATPase inhibitors were also made. Permeation characteristics of drug were evaluated by putting 1 ml formulation on freshly excised cornea fixed between donor and receptor compartments of an all-glass modified Franz diffusion cell and measuring the drug permeated in the receptor by spectrophotometry at 265 nm, after 120 min. Statistical analysis was done by one-way analysis of variance (ANOVA) followed by Dunnett's test or paired t-test. Increase in drug concentration in the formulation resulted in an increase in the quantity permeated but after a certain level increase in permeation with increase in concentration was minimal. Aqueous drops made isotonic with dextrose showed decreased permeation through paired cornea compared with aqueous drops made isotonic with NaCl from 1% w/v ascorbic acid solution suggesting likely involvement of Na(+) co-transporter but there was decreased permeation through 0.5% w/v ascorbic acid solution made isotonic with NaCl as compared to solution made isotonic with dextrose. Further aqueous drops containing Na(+)K(+)-ATPase inhibitor {MAG-Mono Ammonium Glycyrrhizinate (25 μmol)} showed decreased corneal permeation from 0.5% w/v ascorbic acid solution but there was not significant decrease from 1% ascorbic acid solution since MAG is a competitive inhibitor of ascorbic acid. Aqueous drops containing Na(+)K(+)-ATPase inhibitor {MAG (50 μmol) or Ouabain (1 mmol)} showed decreased corneal permeation of ascorbic acid compared with control from 1% ascorbic acid solution confirming the involvement of Na(+) co-transporter.